Eva Lorenz1, Maria Blettner1, Björn Lange2, Marcus Schmidt3, Astrid Schneider1, Lukas Schwentner4, Daniel Wollschläger1, Hiltrud Merzenich1. 1. Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany. 2. Center for Cardiology, University Medical Center Mainz, Mainz, Germany. 3. Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany. 4. Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Abstract
BACKGROUND: Advances in oncological therapy have significantly improved breast cancer survival; therefore comorbid conditions are becoming more relevant. We investigated the prevalence of prior cardiovascular diseases and risk factors in patients with breast cancer compared to those in the general female population in Germany. METHODS: The PASSOS heart study is a retrospective multicenter cohort study on cardiac late effects in breast cancer patients treated between 1998 and 2008. We analyzed the frequencies of cardiac diseases and cardiovascular risk factors in patients from this cohort as documented in anesthesia protocols compared to self-reported frequencies in the general female population in Germany. RESULTS: 3,496 patients aged between 40 and 79 years who underwent breast surgery were considered for analysis. The age-standardized prevalence of cardiac diseases or cardiovascular risk factors was 6.75 versus 7.52% and 69 versus 80.92%, respectively. Coronary heart disease (3.96 vs. 5.18%) and angina pectoris (0.37 vs. 1.03%) prevalence was lower in breast cancer patients, while non-fatal myocardial infarction (2.06 vs. 1.81%) and stroke (2.64 vs. 2.34%) were more frequent (not statistically significant). CONCLUSION: Pre-existing cardiac diseases and cardiovascular risk factors are common in both study populations, being slightly less frequent in the PASSOS cohort. When making therapy decisions, the cardiac risk profile should be carefully monitored and taken into account.
BACKGROUND: Advances in oncological therapy have significantly improved breast cancer survival; therefore comorbid conditions are becoming more relevant. We investigated the prevalence of prior cardiovascular diseases and risk factors in patients with breast cancer compared to those in the general female population in Germany. METHODS: The PASSOS heart study is a retrospective multicenter cohort study on cardiac late effects in breast cancer patients treated between 1998 and 2008. We analyzed the frequencies of cardiac diseases and cardiovascular risk factors in patients from this cohort as documented in anesthesia protocols compared to self-reported frequencies in the general female population in Germany. RESULTS: 3,496 patients aged between 40 and 79 years who underwent breast surgery were considered for analysis. The age-standardized prevalence of cardiac diseases or cardiovascular risk factors was 6.75 versus 7.52% and 69 versus 80.92%, respectively. Coronary heart disease (3.96 vs. 5.18%) and angina pectoris (0.37 vs. 1.03%) prevalence was lower in breast cancer patients, while non-fatal myocardial infarction (2.06 vs. 1.81%) and stroke (2.64 vs. 2.34%) were more frequent (not statistically significant). CONCLUSION: Pre-existing cardiac diseases and cardiovascular risk factors are common in both study populations, being slightly less frequent in the PASSOS cohort. When making therapy decisions, the cardiac risk profile should be carefully monitored and taken into account.
Entities:
Keywords:
Breast cancer patients; Cardiovascular late effects; Cardiovascular prevalence; German general population; Prevalence comparison
Authors: Daniel Wollschläger; Hiltrud Merzenich; Lukas Schwentner; Wolfgang Janni; Thomas Wiegel; Detlef Bartkowiak; Achim Wöckel; Marcus Schmidt; Heinz Schmidberger; Maria Blettner Journal: Breast Cancer Res Treat Date: 2017-03-28 Impact factor: 4.872
Authors: Hiltrud Merzenich; Detlef Bartkowiak; Heinz Schmidberger; Marcus Schmidt; Lukas Schwentner; Thomas Wiegel; Achim Woeckel; Daniel Wollschläger; Maria Blettner Journal: Breast Cancer Res Treat Date: 2016-11-01 Impact factor: 4.872
Authors: P Kamtsiuris; M Lange; R Hoffmann; A Schaffrath Rosario; S Dahm; R Kuhnert; B M Kurth Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2013-05 Impact factor: 1.513
Authors: Maryska L G Janssen-Heijnen; Huub A A M Maas; Saskia Houterman; Valery E P P Lemmens; Harm J T Rutten; Jan Willem W Coebergh Journal: Eur J Cancer Date: 2007-08-02 Impact factor: 9.162
Authors: Axel Schlitt; Karin Jordan; Dirk Vordermark; Jürgen Schwamborn; Thorsten Langer; Christoph Thomssen Journal: Dtsch Arztebl Int Date: 2014-03-07 Impact factor: 5.594